$87.07
0.72% yesterday
Nasdaq, Sep 18, 10:19 pm CET
ISIN
US88023B1035
Symbol
TEM

Tempus AI Stock price

$87.07
+8.62 10.99% 1M
+41.33 90.36% 6M
+53.31 157.91% YTD
+35.76 69.69% 1Y
+50.07 135.32% 3Y
+50.07 135.32% 5Y
+50.07 135.32% 10Y
+50.07 135.32% 20Y
Nasdaq, Closing price Thu, Sep 18 2025
+0.62 0.72%

Key metrics

Basic
Market capitalization
$15.1b
Enterprise Value
$15.6b
Net debt
$506.7m
Cash
$291.3m
Shares outstanding
173.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
15.9 | 11.9
EV/Sales
16.4 | 12.3
EV/FCF
negative
P/B
48.9
Financial Health
Equity Ratio
6.1%
Return on Equity
-1,324.7%
ROCE
-19.5%
ROIC
-17.5%
Debt/Equity
2.6
Financials (TTM | estimate)
Revenue
$952.0m | $1.3b
EBITDA
$-220.3m | $4.6m
EBIT
$-234.8m | $-60.3m
Net Income
$-199.7m | $-132.6m
Free Cash Flow
$-72.9m
Growth (TTM | estimate)
Revenue
59.8% | 83.4%
EBITDA
67.3% | 100.7%
EBIT
65.7% | 91.3%
Net Income
74.7% | 82.2%
Free Cash Flow
77.5%
Margin (TTM | estimate)
Gross
60.7%
EBITDA
-23.1% | 0.4%
EBIT
-24.7%
Net
-21.0% | -10.4%
Free Cash Flow
-7.7%
More
EPS
$-1.2
FCF per Share
$-0.4
Short interest
19.0%
Employees
-
Rev per Employee
-
Show more

Is Tempus AI a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Tempus AI Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Tempus AI forecast:

11x Buy
61%
7x Hold
39%

Analyst Opinions

18 Analysts have issued a Tempus AI forecast:

Buy
61%
Hold
39%

Financial data from Tempus AI

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
952 952
60% 60%
100%
- Direct Costs 374 374
30% 30%
39%
578 578
87% 87%
61%
- Selling and Administrative Expenses 664 664
21% 21%
70%
- Research and Development Expense 134 134
4% 4%
14%
-220 -220
67% 67%
-23%
- Depreciation and Amortization 15 15
39% 39%
2%
EBIT (Operating Income) EBIT -235 -235
66% 66%
-25%
Net Profit -200 -200
75% 75%
-21%

In millions USD.

Don't miss a Thing! We will send you all news about Tempus AI directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tempus AI Stock News

Neutral
PRNewsWire
4 days ago
Definitive agreement to accelerate adoption of Renalytix's FDA-approved, Medicare reimbursed kidneyintelX.dkd test to slow kidney disease progression and improve patient outcomes NEW YORK , Sept. 15, 2025 /PRNewswire/ -- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), today announced an agreement with Tempus AI, Inc. (NASDAQ: TEM) to make kidneyintelX.dkd prognostic blood testing more widely availabl...
Positive
Invezz
7 days ago
Tempus AI stock price surged to a record high on Wednesday after the healthcare-focused artificial intelligence company announced a major breakthrough from the Food and Drug Administration (FDA). It jumped to a high of $91, which coincided with the highest point in February this year.
Positive
Forbes
7 days ago
Great news for Tempus AI stock! The company has just received FDA approval for an upgraded version of its Tempus Pixel platform — a cardiac imaging system that uses advanced AI to deliver highly accurate images of a patient's heart.
More Tempus AI News

Company Profile

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Head office United States
CEO Eric Lefkofsky
Website www.tempus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today